The role of chronic muscle (in)activity on carnosine homeostasis: a study with spinal-cord injured athletes

Running title: Chronic muscle inactivity and muscle carnosine content

Kleiner Nemezio[1], Guilherme de Carvalho Yamaguchi[1], Ana Paula Boito Ramkrapes[2], Mariane Leichsenring Schulz[3], Igor Luchini Baptista[4]; Luiz Augusto Riani[1], Lívia de Souza Gonçalves[1], Craig Sale[5], Marisa Helena Gennari de Medeiros[3], Bruno Gualano[1], Guilherme Giannini Artioli[1]

[1] Applied Physiology & Nutrition Research Group; School of Physical Education and Sport, Faculdade de Medicina, Divisão de Reumatologia, Universidade de São Paulo, SP, Brazil.

[2] Faculty of Physical Education, University of Campinas, SP, Brazil.

[3] Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brasil.

[4] Faculdade de Ciências Aplicadas, Universidade Estadual de Campinas, Campinas, SP, Brasil.

[5]Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, Nottingham Trent University, UK.

Corresponding author:
Guilherme G Artioli
E-mail: artioli@usp.br
Telephone number: +55 (11)26481337

Abstract

To examine the role of chronic (in)activity on muscle carnosine (MCarn) and how chronic (in)activity affects MCarn responses to β-alanine supplementation in spinal-cord injured athletes, sixteen male athletes with paraplegia were randomized (2:1 ratio) to receive β-alanine (n=11) or placebo (PL, n=5). They consumed 6.4 $g \cdot d^{-1}$ of β-alanine or PL for 28 days. Muscle biopsies of the active *deltoid* and the inactive *vastus lateralis* (VL) were taken before and after supplementation. MCarn in the VL was also compared with the VL of a group of individuals without paraplegia (n=15). MCarn was quantified in whole muscle and in pools of individual fibers by High-performance Liquid Chromatography. MCarn was higher in chronically inactive VL *vs.* well-trained *deltoid* (32.0±12.0 *vs.* 20.5±6.1 $mmol \cdot kg^{-1}$ DM; p=0.018). MCarn was higher in inactive *vs.* active VL (32.0±12.0 vs. 21.2±7.5 $mmol \cdot kg^{-1}$ DM; p=0.011). In type-I fibers, MCarn was significantly higher in the inactive VL than in the active deltoid (38.3±4.7 *vs.* 27.3±11.8 $mmol \cdot kg^{-1}$ DM, p=0.014). MCarn increased similarly between inactive VL and active *deltoid* in the β-alanine group (VL: 68.9±55.1%, p=0.0002; deltoid: 90.5±51.4%, p<0.0001), with no changes in the PL group. MCarn content was higher in the inactive VL than in the active *deltoid* and the active VL, but this is probably a consequence of fiber type shift (type I to type II) that occurs with chronic inactivity. Chronically inactive muscle showed an increase in MCarn after BA supplementation equally to the active muscle, suggesting that carnosine accretion following β-alanine supplementation is not influenced by muscle inactivity.

Keywords: muscle inactivity, muscle activity, carnosine, β-alanine, homeostasis.

69 **Introduction**

70 Carnosine is a multifunctional dipeptide abundantly expressed in human skeletal
71 muscle, where it is thought to play important physiological roles, including pH
72 regulation (1, 12) , Ca^{2+} handling (14) and reactive aldehyde detoxification (3, 9). The
73 availability of β-alanine, the rate-limiting precursor of carnosine synthesis, is the most
74 influential factor affecting muscle carnosine content (MCarn) (22). Studies have
75 consistently shown that β-alanine supplementation increases MCarn (33), which has
76 been associated with improved high-intensity exercise performance (34) and potentially
77 improved health (2). Conversely, decreased MCarn during the washout period following
78 β-alanine has been associated with the return of exercise tolerance to pre-
79 supplementation levels (37).

80 While β-alanine intake, either ingested from food or supplements, increases
81 MCarn in a dose-dependent, saturable fashion (33), it remains unclear whether other
82 stimuli can also affect MCarn. There is evidence indicating that exercise can modulate
83 carnosine homeostasis, with cross-sectional studies showing that sprint- and strength-
84 trained athletes have higher MCarn than sedentary and endurance-trained individuals
85 (31, 36). Although this is suggestive of an effect of high-intensity exercise on carnosine
86 synthesis, possibly due to an effect of long-term exposure to acidosis as an adaptive
87 trigger, several subsequent longitudinal studies did not confirm that chronic exercise
88 training can increase MCarn (4, 15, 20, 27-29). The lack of control over the dietary
89 intake of β-alanine, the lack of control for fiber type shifting alongside training, and
90 purportedly insufficient training stimuli might, however, limit the interpretation of these
91 studies. Type II fibers contains approximately 1.5 times more carnosine than type I
92 fibers (21, 23), which highlights the importance of accounting for changes in fiber type
93 distribution when fiber shift can occur.

94 De Salles Painelli et al. (11) showed that 12 weeks of high-intensity interval
95 training increased MCarn in vegetarians, a population that consumes virtually no β-
96 alanine in the diet. In contrast, Hoetker et al. (24) showed that low-intensity training
97 increased muscle carnosine, while high-intensity training decreased muscle carnosine.
98 The potential reasons for the disparity between these two studies are not immediately
99 apparent and it is clear that there is a requirement to further investigate whether or not
100 acute exercise can modulate the carnosine content in skeletal muscle.

101 It also remains uncertain whether exercise training or training status can affect
102 carnosine accretion in response to β-alanine supplementation. Bex et al. (7) showed that

muscle groups under higher training loads respond to β-alanine supplementation with greater carnosine accretion in comparison with muscle groups under lower training loads. Bex et al. (6) showed increased carnosine accretion in response to β-alanine supplementation in individuals who undertook exercise training when compared with non-trained controls. In both studies (6, 7), muscle carnosine was measured with magnetic resonance spectroscopy, a method that has been shown to be less reliable than more direct measures of carnosine content, such as chromatography-based techniques from muscle biopsy samples (10). In contrast, using high-performance liquid chromatography (HPLC), Kendrick et al. (28) showed similar carnosine accretion between trained and untrained muscle groups in response to β-alanine supplementation. Out of the inconsistent findings in the literature, to date, it remains unknown whether physical activity modulates MCarn or whether it enhances MCarn responses to β-alanine supplementation.

To understand the role of muscle activity on muscle carnosine homeostasis, we examined the extremes of the muscle activity spectrum (*i.e.*, chronic long-term athletic training *vs.* chronic long-term muscle inactivity) by investigating well-trained athletes with spinal-cord injury. In these athletes we compared their chronically trained muscle (*deltoid*) with their chronically inactive muscle (*vastus lateralis*), both at baseline and in response to β-alanine supplementation. We hypothesized that paralyzed muscles would display lower carnosine levels at baseline and reduced carnosine loading in response to β-alanine supplementation, in comparison with active muscles.

Methods

Participants

Twenty-three men with spinal cord injury and paraplegia were screened for eligibility. Inclusion criteria were: *1)* participation in a structured exercise training program for ≥6 h per week for ≥6 months prior to participation; *2)* spinal-cord injury with loss of motor function of the lower limbs corresponding to the American Spinal Cord Injury Association Scale A or B for ≥1 year and *3)* age 18-45 years. Exclusion criteria were: *1)* diagnosed with a chronic disease that would preclude participation in the study and *2)* use of supplements containing creatine or β-alanine ≤6 months prior to participation. Before signing the written consent form, all participants were fully informed about benefits and risks involved with participation. All procedures were

approved by the Institutional Ethics Committee before the commencement of the study (#41495115.0.0000.5391) and complied with the Declaration of Helsinki.

One individual did not meet the inclusion criteria (sedentary) while six other individuals were unavailable for participation. Sixteen volunteers were then randomly allocated in a 2:1 ratio to receive β-alanine (n=11) or placebo (n=5). An unbalanced 2:1 allocation ratio was used due to the limited potential participant pool for this study, the invasive nature of the study and to increase the number of observations in the β-alanine group. Two participants (one from each group) dropped-out after the initial biopsy session and therefore did not participate in the post-supplementation analyses. We were unable to obtain usable muscle samples from the *vastus lateralis* of 3 participants (one from the β-alanine group and 2 from the placebo group).

The participants had been training for 10.5±3.7 years at the time of the study; all of them reported that they performed upper-body strength, arm crank, mobility and shoulder stability training 2-5 times per week in addition to their sport-specific training, totalling 573±102 min of training per week. All participants reported the use of passive leg exercises, but none of them used electrical stimulation of the lower limbs. Participant general characteristics are displayed in Table 1, while specific information about individual spinal cord injury is displayed in Table 2.

Table 1: Participant general characteristics.

	β-alanine (n=11)	**Placebo (n=5)**	**p**
Age (y)	36.1 ± 3.9	34.6 ± 8.1	0.62
Body mass (kg)	71.9 ± 11.8	67.8 ± 11.9	0.52
Length (cm)	176 ± 8.6	172 ± 6.9	0.38
BMI (kg/m^2)	23.2 ± 3.0	22.9 ± 3.8	0.89
Time since injury (y)	14.1 ± 3.7	13.4 ± 7.3	0.80
VO_{2peak} (L·min^{-1})	1.3 ± 0.6	1.7 ± 0.8	0.30
$Power_{max}$ (W)	71.2 ± 42.5	91.1 ± 53.7	0.44

BMI: body mass index; $Power_{max}$: maximum load attained in a progressive arm-crank exercise test to volitional fatigue. p-values refer to independent samples *t* tests.

Table 2: Individual spinal cord injury characteristics and training status of each participant.

Participant	ASIA classification	Lesion level	Training status	Sport
β-alanine				
1	B	C6-C7	Amateur athlete	Artistic Gymnastics
2	A	T12	Competitive athlete	Cross-training
3	B	T12-L1	Competitive athlete	Wheelchair basketball
4	B	L1-L2	Competitive athlete	Wheelchair basketball
5	B	C6-C7	Amateur athlete	Brazilian Jiu Jitsu
6	B	T3	Competitive athlete	Endurance hand-bike
7	B	C6-C7	Competitive athlete	Wheelchair rugby
8	B	T2-T3	Competitive athlete	Wheelchair rugby
9	A	C7	Competitive athlete	Wheelchair rugby
10	A	C5	Competitive athlete	Wheelchair rugby
11	A	C6-C7	Competitive athlete	Wheelchair rugby
Placebo				
12	B	T12-L1	Competitive athlete	Paralympic archery
13	B	T5-T6	Competitive athlete	Endurance hand-bike
14	B	L2	Competitive athlete	Wheelchair basketball
15	B	T9	Amateur athlete	Endurance hand-bike
16	B	C7	Competitive athlete	Wheelchair rugby

ASIA: American Spinal Cord Injury Association.

Experimental design

This study was designed to test the influence of chronic exercise training and muscle inactivity on *1)* MCarn and *2)* MCarn accumulation in response to β-alanine supplementation. Thus, we first performed a cross-sectional analysis to compare MCarn in trained (*deltoid*) *vs.* paralyzed (*vastus lateralis*) muscles in highly trained athletes with paraplegia. Since this within-individual analysis only allows for the comparison between different muscle groups (*i.e.*, *deltoid vs. vastus lateralis*), we conducted a second cross-sectional analysis to compare MCarn between paralyzed *vs.* active muscles in the same muscle group (i.e., *vastus lateralis*). Thus, we compared MCarn in athletes with paraplegia *vs.* MCarn in a group of physically active individuals without paraplegia (n=15 healthy, physically active men; age=28±5 y; body mass=76.2±17.3 kg;

BMI=24.8±3.9) who took part in another study that was being conducted at the same time in our lab and was published elsewhere (37).

In addition to the cross-sectional analyses, we conducted a double-blind, placebo-controlled trial with athletes with paraplegia to compare MCarn in response to β-alanine supplementation in their trained *vs.* paralyzed muscle groups. To account for the effects of chronic training and paralysis on fiber type distribution and for the influence of the higher carnosine levels in type II fibers (11, 22), MCarn was determined not only in whole muscle, but also in single muscle fibers. Groups were equalized according to the $Power_{max}$ by ranking the participants within blocks of 4 individuals and using the block randomization method (www.random.org). All participants with paraplegia were asked to attend to the laboratory on three different occasions. In the first visit, body mass, body length and peak oxygen consumption were measured. In a second visit, 2-7 days apart, muscle biopsies of the *deltoid* (trained muscle) and the *vastus lateralis* (paralyzed muscle) were taken for pre-supplementation (PRE) MCarn determination. A 28-day β-alanine supplementation period commenced on the next day, after which (POST) another biopsy of the *deltoid* and the *vastus lateralis* was taken. All athletes and coaches were instructed to maintain athletes' training regimens and dietary habits across the supplementation period, which was verbally confirmed upon their visit after supplementation. The experimental procedures for the participants without paraplegia were described elsewhere (37), but in this study we are only interested in their baseline MCarn as this will serve as a reference of typical values in non-paralyzed *vastus lateralis*.

Preliminary Testing

Body mass was measured to the nearest 100 g on a digital scale (100 CH, Welmy, São Paulo, Brazil). Wheelchair weight was first measured without the volunteer. When stabilized, the scale display was reset and the volunteer was transferred back to the wheelchair to determine body mass. Length was measured as the distance between the top of the head of the bottom of the feet, with the individual laid down on a gurney with their knees fully extended and their feet beside one another.

A maximal incremental test was conducted in a mechanically braked arm ergometer (EB 4100, Cefise, Brazil) as previously described (32). The test was initiated with a load corresponding to 25 W (0.3 kilopond at 85 $rev \cdot min^{-1}$), followed by 25 W

212 increments every minute until volitional exhaustion or until the participant could no
213 longer maintain 85 rev·min^{-1}. Breath by breath gas exchange was measured in a gas
214 analyzer (Quark CPET, Cosmed, Rome, Italy) calibrated according to manufacturer
215 instructions. VO_{2peak} was considered the arithmetic mean of the least 30 seconds of the
216 test and $Power_{max}$ was the maximum power attained.
217
218 Supplementation protocol
219 Participants consumed 6.4 g·d^{-1} of either β-alanine (SR CarnoSyn®, Natural
220 Alternatives International, Inc, Carlsbad, CA) or placebo (maltodextrin, Natural
221 Alternatives International, Inc, Carlsbad, CA) for 28 days, totalling an accumulated
222 dose of 179.2 g. The total daily dose was split into 4 individual doses of 1.6 g provided
223 in 0.8 g sustained release tablets, identical in number and appearance. All participants
224 completed a supplementation log; compliance with supplementation was 98±2% of the
225 total dose in β-alanine group and 97±1.5% in placebo group. At the end of the
226 supplementation period, the participants reported which substance they believed they
227 were taking. Three participants in the β-alanine group and 2 in the placebo groups
228 correctly guessed their treatments (Fisher's exact: p=0.6). Two out of the 16 participants
229 reported slight symptoms of paresthesia, one from β-alanine group and the other from
230 the placebo group.
231
232 Muscle biopsies
233 Approximately 70-100 mg of wet muscle were obtained from the mid portion of
234 the *vastus lateralis* and from the most lateral and voluminous part of the *deltoid* under
235 local anesthesia (3 ml lidocaine 1%), using the percutaneous Bergstrom needle biopsy
236 technique (5) modified with suction. Samples were obtained PRE and POST
237 supplementation from the same locations, as close as possible to one another, and
238 immediately frozen in liquid nitrogen. Before analyses, the samples were freeze dried
239 overnight for 16 h, and then all visible blood, fat and connective tissue were removed.
240
241 Quantification of MCarn in whole muscle
242 Carnosine was quantified in extracts of whole muscle by High-performance
243 Liquid Chromatography (LC-10vp, Shimadzu, Japan) coupled with ultraviolet detection
244 at 214 nm (SPD-10vp, Shimadzu, Japan), using the method described by Mora et al.
245 (30). Approximately 3-5 mg of freeze-dried muscle were manually powdered and

246 deproteinized in an acid extraction solution [0.5 M $HClO_4$, 1 mM EDTA; 1:50 sample
247 weight (mg):volume (µl)] via intermittent vortex bursts for 10 min (30s on, 30 s resting
248 on ice). The extracts were then centrifuged (3 min, 5000 g at 4° C) and the supernatant
249 was then neutralized with 2.1 M $KHCO_3$ (1:4 v:v) and filtered through a 0.2 µm pore
250 size centrifugal filter tube. Chromatographic separation was performed using an Atlantis
251 HILIC silica column (4.6 × 150 mm, 3 µm; Waters, Massachusetts, USA) and an
252 Atlantis Silica column guard (4.6 × 20 mm, 3 µm). Briefly, the method uses mobile
253 phase A [0.65 mM ammonium acetate, in water/acetonitrile (25:75) (v/v)], and mobile
254 phase B [4.55 mM ammonium acetate, in water/acetonitrile (70:30)], both adjusted to
255 pH 5.5. The separation condition was: linear gradient from 0 to 100% of mobile phase B
256 for 13 min at a flow rate of 1.4 $mL \cdot min^{-1}$. All samples were analyzed in duplicate with
257 the intra-assay coefficient variation being 2.03% and the coefficient of variation
258 between different biopsies from the same site being 3.95% (10).
259
260 Quantification of MCarn in pools of individual fibers
261 Approximately 30-40 fibers were isolated and cut in two halves (0.5-1 mm). One
262 half was used for MHC determination while the remaining piece was weighed on a
263 quartz-fiber fish-pole balance to the nearest 0.01 µg, as previously described (11, 28).
264 Fibers of the same MHC type were pooled and metabolite was extracted by adding
265 ultrapure water and vortexing for 10 min (30-s bursts interspersed with 30-s cooling
266 periods on ice). Carnosine was then quantified by HPLC (Hitachi, Schaumburg, IL)
267 with pre-column derivatization coupled to a fluorescence detector as previously
268 described (13). Metabolite separation was undertaken in a Hypersil ODS analytical
269 column (3 µm, 150 x 4.6 mm I. D., Shandon, Runcom, UK) at 23 ºC. A binary gradient
270 formed from solvent A [12.5 mM sodium acetate, pH 7.2 tetrahydrofuran (995:5, v/v)]
271 and solvent B [12.5 mM sodium acetate, pH 7.2 - methanol-acetonitrile (500:350:150,
272 v/v)] was used with the following gradient: 0 to 1.5 min, 0% solvent B; 1.5 to 10 min,
273 35% B; 10 to 26 min, 60% B; 26 to 30 min, 100% B; 30 to 35 min, 100% B; 35 to 45
274 min, 0% B. Flow-rate was 2.0 $ml \cdot min^{-1}$ in the initial 10 minutes, and gradually
275 decreased to 1.0 ml·min-1 at 26 min until finish. Excitation and emission wavelengths
276 were 340 nm and 450 nm. The derivatization reagent was kept in the dark at 2°C and
277 prepared by mixing 80 µL of OPA (40mg) plus absolute ethanol (800 µL) to 4 µL of β-
278 mercaptoethanol and 1 mL of a 0.4M borate buffer (pH 9.65). Extract and reagent (1:1
279 v:v) were reacted for 30 s prior to injection. Fresh derivatization reagent was used with

each new sample batch. All samples were analyzed in duplicate and the intra-assay coefficient of variation was 8.8% in pools of single fibers. Quantification of both chromatographic methods was performed by integrating peak areas.

Myosin heavy-chain isoform characterization

Myosin heavy-chain isoform was characterized in single fibers and in whole muscle by dissolving (mixing with a vortex) a half fiber or ~3 mg of freeze-dried muscle sample in extraction buffer (0.06 M tris-hydroxymethylaminomethane pH 6.8, 1% w/v sodium dodecyl sulphate, 0.6%w/v EDTA, 15% w/v glycerol, 5% v/v mercaptoethanol, and bromophenol blue) followed by SDS-PAGE electrophoresis, as described by Kendrick et al. (28). MHC isoform type was determined as described by Galpin et al (16). Ten micro-litters of the extract were loaded in a polyacrylamide gel and ran for ~28h at 4°C. Protein was revealed using a silver staining kit (PlusOne, Cytiva). Band intensity was quantified in the ImageJ software and used for individual fiber typing or for whole muscle MHC distribution.

Dietary β-alanine intake assessment

β-alanine intake was assessed with three food diaries undertaken on 3 non-consecutive days (two weekdays and one weekend day) following the instructions of a registered nutritionist. β-alanine intake through consumption of fish, poultry and meat was estimated from the data of Jones et al. (25).

Statistical analysis

Participants general characteristics (age, body mass, length, body mass index, VO_{2peak}, $Power_{max}$, and time since injury) were compared between groups with unpaired t-tests. Linear mixed models (proc mixed, SAS University Edition) were used to compare whole muscle MCarn between *deltoid* and *vastus lateralis* before and after β-alanine or placebo supplementation. Group, time and muscle group were fixed factors, whilst participants were random factors. Linear mixed models were also used for dietary β-alanine intake data, with group and time being fixed factors. Four covariance matrices (unstructured, compound symmetric, autoregressive and toeplitz) were tested, with the best fit being chosen using the lowest BIC (Bayesian Information Criteria) value.

Hypothesis-driven, single degree-of-freedom contrast analysis was used to identify significant differences whenever a significant main interaction effect was observed. Delta post-pre supplementation was calculated and compared between muscle groups with Welch unpaired t-test for unbalanced samples (RStudio v.4.0.0).

For MCarn measured in pools of single fibers, linear mixed models did not converge (due to unbalanced sample sizes and missing sub-type fiber data, as most samples had no type I or type II MHC), meaning that data sets for each fiber type were analyzed separately. For the baseline data, β-alanine and placebo groups were pooled and a Welch unpaired t-test (RStudio v.4.0.0) for unbalanced sample sizes was used to compare MCarn between the *deltoid* and *vastus lateralis* muscles and to compare MCarn in the *vastus lateralis* between athletes with paraplegia and individuals without paraplegia; MCarn in type I *vs.* type II fibers were compared within the same muscle group of the same individuals with t-test for dependent samples (RStudio v.4.0.0). For the MCarn responses to β-alanine supplementation, fast MHC subtypes were pooled and delta post-pre supplementation was deemed as the response variable (data from the placebo group was excluded due to very low or zero number of observations in some instances) and compared with a two-way general linear model (type III, for unbalance samples) where muscle group (*deltoid vs. vastus lateralis*) and fiber type (type I *vs.* type II) were fixed factors (SPSS v.14). Data are reported as mean±SD and the significance level was set at $p<0.05$.

Results

<u>Role of chronic muscle (in)activity on muscle carnosine</u>

In the athletes with paraplegia, MCarn was significantly higher in the chronically inactive *vastus lateralis* muscle in comparison with their well-trained *deltoid* muscle (main effect of muscle group: F=10.7, p=0.006; figure 1, panel A). Higher MCarn was also shown in the inactive *vastus lateralis* when compared to the active *vastus lateralis* of individuals without paraplegia (p=0.011, 95%CI: 2.7–18.8; figure 1, panel B).

Figure 1: Individuals (white circles) and mean±SD group values for carnosine content in whole muscle. Panel A: cross-sectional analysis comparing the active *deltoid* muscle and the paralyzed *vastus lateralis* muscle in athletes with paraplegia (p-value refer to

the main effect of muscle group in the mixed models). Panel B: cross-sectional analysis comparing the paralyzed *vastus lateralis* muscle in athletes with paraplegia *vs* the active *vastus lateralis* in a group of physically active participants without paraplegia that took part in another study (data published in Yamaguchi et al. 2020 (37); p-value refer to Welch unpaired t-tests for unbalanced samples).
Note: data from athletes with paraplegia refer to baseline (pre-supplementation) β-alanine and placebo groups pooled.

Importantly, chronic muscle inactivity in spinal cord injury was associated with a substantive increase in fast MHC isoform distribution (Figure 2), which could influence whole muscle MCarn and become a confounding factor in our analysis, since MCarn is ~1.5 times higher in type II than in type I fibers (21, 23). Therefore, we also determined MCarn in single fibers. In type I fibers, MCarn was significantly higher in the inactive *vastus lateralis* muscle in comparison with the active *deltoid* muscle (p=0.014, 95%CI: -19.5–-2.6; figure 3, panel A). There were no significant differences in MCarn in type IIa between the active and inactive muscles (p=0.851, 95%CI: -12.7–15.2; figure 2, panel B), as was the case for hybrid type IIx/IIa fibers (p=0.53, 95%CI: -14.1–7.7; figure 3, panel C). We were unable to compare carnosine content in type IIx fibers because they were present in only 2 out of the 16 samples.

Figure 2. Representative images of silver-stained electrophoresis gel for MHC typing in whole muscle and in single fibers (panel A). MHC isoform distribution in the active deltoid muscle and in the paralyzed *vastus lateralis* muscle in athletes with paraplegia (β-alanine and placebo pooled) at baseline (panels B and C).

Figure 3: Individual (white circles) and mean±SD group values for muscle carnosine content in pools of single fibers in the paralyzed *deltoid* muscle and in the active *vastus lateralis* muscle in athletes with paraplegia. Panels A, B and C display comparisons between muscle groups. Panels D and E display comparisons within muscle groups.
Note: Data refer to baseline (pre-supplementation) β-alanine and placebo groups pooled. p-values for between-muscle group comparisons were calculated with Welch unpaired t-tests for unbalanced samples while p-values for within-muscle group comparisons were

calculated with t-test for dependent samples. Different sample sizes are due to the absence of fiber types in some of the samples.

Role of chronic muscle (in)activity on muscle carnosine responses to β-alanine supplementation

Significant increases in MCarn were shown in both *deltoid* and *vastus lateralis* muscles in the β-alanine, but not in the placebo group (group-by-time-by-muscle interaction: F=6.61, p=0.0045; figure 4, panel A). Between-group contrast analyses confirmed that post-supplementation MCarn was significantly higher in the β-alanine group than in placebo group (*deltoid*: p=0.0046; *vastus lateralis*: p=0.024). MCarn increased 68.9±55.1% in the *vastus lateralis* (within-group effect: p<0.0001) and 90.5±51.4% in the *deltoid* (within-group effect: p=0.0002) in the β-alanine group. No significant differences were shown for the delta changes between the *deltoid* and *vastus lateralis* in either the β-alanine (p=0.653; 95%CI:-10.6–6.9; figure 4, panel B) or placebo (p=0.623; 95%CI:-6.8–4.6; figure 4, panel B) group.

Figure 4: Individual (white circles) and mean±SD muscle carnosine content before and after β-alanine supplementation in *deltoid* and *vastus lateralis* in the β-alanine and placebo groups (panel A). Post-pre absolute delta changes in muscle carnosine in the β-alanine and placebo groups (panel B).
Note: In panel A, group-by-time-by-muscle interaction effect: F=6.61, p=0.0045; p-values were calculated with single-degree-of-freedom contrast analyses in the mixed models. In panel B, p-values were calculated with Welch unpaired t-tests for unbalanced samples.

To account for the effect of MHC isoform distribution on the MCarn responses to β-alanine supplementation, MCarn accretion was compared in pools of single fibers between the *deltoid* and *vastus lateralis*. No effects of fiber type (F=0.40, p=0.53), muscle group (F=0.19, p=0.68) or fiber type by muscle group interaction (F=2.37, p=0.13) were shown (figure 5).

Figure 5: Individual (white circles) and mean±SD single fiber muscle carnosine accretion in response to β-alanine supplementation in *deltoid* and *vastus lateralis.* Type II fibers represent IIa and hybrid IIa/IIx fibers pooled.
General linear model: fiber type (F=0.40, p=0.53); muscle group (F=0.19, p=0.68); fiber type by muscle group interaction (F=2.37, p=0.13).

Dietary β-alanine intake

The estimated β-alanine intake was similar between groups and across the study period (PRE: β-alanine=0.8±0.6g, placebo:0.4±0.3g; POST: β-alanine=1.1±1g; placebo:0.4±0.2g) (main effect of group: F=2.71, p=0.128; group by time interaction: F=0.2, p=0.664).

Discussion

By comparing a habitually highly active muscle (the *deltoid*) with a chronically inactive muscle (the *vastus lateralis*) in athletes with spinal cord injury, we have been able to show that not only chronic muscle inactivity does not result in a significant reduction in MCarn, but that the MCarn content in the chronically inactive *vastus lateralis* muscle was higher than in the highly active *deltoid* muscle. This result was further confirmed in a retrospective analysis that showed higher MCarn in the paralyzed v*astus lateralis* muscle of athletes with paraplegia than in the *vastus lateralis* muscle of physically active individuals without paraplegia. Whilst this result might not necessarily seem intuitive, previous studies have shown that prolonged muscle inactivity (>10 months) results in a dramatic muscle fiber type shift, from type I to type II (19, 35). Indeed, we showed that 95% of the fibers in the chronically inactive *vastus lateralis* muscle were fast MHC, whilst the distribution was closer to 50:50 (slow:fast MHC) in the highly active *deltoid* muscle and it is typically 40:60 (slow:fast) in non-paralyzed *vastus lateralis* (8). This suggests that higher MCarn content in the inactive *vastus lateralis* could be, at least in part, explained by a type I to II shift, suggesting that it is the predominance of type II muscle fibers in paralyzed muscles that could account for the elevated MCarn to a much greater extent than muscle paralysis *per se*. Increased type II fiber distribution can increase whole muscle MCarn because carnosine in type II fibers is ~1.5 times higher than in type I fibers (11, 21, 23). To account for this effect, we examined MCarn in pools of isolated fibers and showed no differences between

vastus lateralis and *deltoid* muscles in type II fibers.

Although the increase in whole muscle MCarn seemed to occur mainly due to fiber type shifts, in type I fibers a significant higher MCarn was shown, thereby suggesting that chronic muscle inactivity could increase MCarn, at least in type I fibers. Carnosine is typically higher in type II than in type I fibers (11, 21, 23), which we confirmed in the active deltoid muscle in the present study. Interestingly, in the paralyzed vastus lateralis, MCarn in type I fibers was not only comparable to type II fibers in the same paralyzed muscle, but also to the MCarn typically shown in type II fibers in other studies (11, 23). These data further reinforce the notion that chronic inactivity may increase MCarn in type I fibers only. Hence, increased MCarn in type I fibers can also account, although to a lesser extent, for the increased whole muscle MCarn. It is important to highlight, however, that type I fibers were not present in many of the samples obtained; in fact, only 4 samples had type-I fibers to be analysed and caution should be exercised in interpreting these data.

In spite of the limited strength of this evidence, we can speculate that the apparent higher carnosine levels in type I fibers in the inactive muscle might arise from an adaptive mechanism to help protect against excessive ROS formation that is typically found in atrophic conditions (18). This mechanism might involve improved efficiency of β-alanine transport into cells. Jung et al. (26) found that TauT expression, a major β-alanine transporter, is elevated in spinal cord motor neurons of Amyotrophic Lateral Sclerosis transgenic (G93A) mice, suggesting that TauT expression partially protects motor neurons by compensating for oxidative stress. Since oxidative stress is one of the main processes involved in muscle atrophy after spinal cord injury (18), these findings provide some support to the hypothesis that similar mechanisms can occur in chronically paralyzed skeletal muscle. We, unfortunately, were unable to assess protein and gene expression levels in our samples due to the very limited availability of usable material in the muscle specimens, which we acknowledge as a limitation of our study. Thus, this hypothesis remains to experimentally confirmed.

Importantly, β-alanine supplementation increased MCarn to a similar extent in both the active *deltoid* and the inactive *vastus lateralis*. This indicates that muscle (in)activity has no influence on the muscles ability to respond to β-alanine supplementation. This was confirmed in both type I and type II fibers, although the type I fiber dataset is limited due to the reduced number of type I fibers in the paralyzed

481 *vastus lateralis.* Our data are in agreement with the study of the Kendrick et al. (28) that
482 showed similar carnosine accretion between trained and untrained muscle groups in
483 response to β-alanine supplementation. On the other hand, our data disagrees with those
484 by Bex et al. (7) who showed superior carnosine accretion in muscle groups under
485 higher training loads in comparison with muscle groups under lower training loads. Our
486 data also seem to contradict those by Bex et al. (6) who showed a tendency for
487 increased carnosine accretion in response to β-alanine supplementation in individuals
488 undergoing exercise training *vs*. non-trained controls. In their study, however, this
489 difference was not confirmed when the two muscle groups (gastrocnemius and soleus)
490 were analysed separately, suggesting a lack of consistency in the effects. In both studies
491 (6, 7), MCarn was determined with magnetic resonance spectroscopy, a method that is
492 less reliable for muscle carnosine quantification than the chromatographic methods used
493 in our (10) and in Kendrick's studies (27, 28). Importantly, our study was the first to
494 address this question using a single fiber approach, where differences in fiber type
495 distribution are controlled. The similar increase between muscle groups and fiber types
496 further indicates that chronic (in)activity has no effect on MCarn accretion in response
497 to β-alanine supplementation, regardless of fiber type distribution. This corroborates
498 early findings by Harris et al. (22) who showed that type I and type II fibers can equally
499 increase MCarn during β-alanine supplementation in active muscle, and also expands
500 this notion to a condition in which muscle activity is virtually absent.
501 The lack of difference in carnosine accretion between active and inactive
502 muscles in response to β-alanine supplementation may seem to be in contrast with our
503 hypothesis of increased β-alanine transport efficiency in type I fibers following chronic
504 muscle inactivity, since the low availability of β-alanine to muscle cells is the most
505 limiting factor for carnosine synthesis (22). However, this seems not to hold true when
506 β-alanine is abundantly available due to supplementation (17). In cases where β-alanine
507 availability is high, β-alanine transport efficiency seems no to influence carnosine
508 synthesis rates and the activity of carnosine synthase appears to become a rate-limiting
509 factor for intramuscular carnosine synthesis (17). This might explain why carnosine
510 content is higher in type I fiber of paralyzed muscles under no β-alanine
511 supplementation (hypothetically due to increased TauT expression), but no differences
512 in carnosine loading was shown following supplementation, even in type I fibers.
513

To conclude, we demonstrated that MCarn is higher in an inactive than in an active, well-trained muscle. However, this is most likely a reflection of higher type II-fiber distribution resulting from muscle fiber shifts in the inactive muscle. Although we showed some evidence that chronic inactivity increases MCarn in type-I fibers, the strength of the evidence is limited due to the low number of observations. Finally, we provided robust evidence that carnosine accretion in chronically inactive muscle in response to β-alanine supplementation was similar to that of an active, well-trained muscle.

Perspectives and significance

By investigating athletes with spinal cord injury, resulting in paraplegia and lower limb immobilization, we demonstrated that sustained muscle (in)activity increases muscle carnosine content, which we suggest is most likely due to type I to type II fiber shift. We also provided some evidence that muscle inactivity might increase carnosine content in type I fibers, possibly as a compensatory effect for the increased oxidative stress that accompanies immobilization. Importantly, carnosine accretion was similar in active and inactive muscles in response to β-alanine supplementation, indicating that chronic (in)activity has no impact on the molecular machinery involved in carnosine synthesis and homeostasis in skeletal muscle. This also suggests that β-alanine supplementation, irrespective of exercise, is the main strategy to increase muscle carnosine.

References

1. **Abe H**. Role of histidine-related compounds as intracellular proton buffering constituents in vertebrate muscle. *Biochemistry Biokhimiia* 65: 757-765, 2000.
2. **Artioli GG, Sale C, and Jones RL**. Carnosine in health and disease. *European journal of sport science* 19: 30-39, 2019.
3. **Baba SP, Hoetker JD, Merchant M, Klein JB, Cai J, Barski OA, Conklin DJ, and Bhatnagar A**. Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein conjugates. *The Journal of biological chemistry* 288: 28163-28179, 2013.
4. **Baguet A, Everaert I, De Naeyer H, Reyngoudt H, Stegen S, Beeckman S, Achten E, Vanhee L, Volkaert A, Petrovic M, Taes Y, and Derave W**. Effects of sprint training combined with vegetarian or mixed diet on muscle carnosine content and buffering capacity. *European journal of applied physiology* 111: 2571-2580, 2011.
5. **Bergstrom J, Furst P, Noree LO, and Vinnars E**. Intracellular free amino acid concentration in human muscle tissue. *J Appl Physiol* 36: 693-697, 1974.
6. **Bex T, Chung W, Baguet A, Achten E, and Derave W**. Exercise training and Beta-alanine-induced muscle carnosine loading. *Front Nutr* 2: 13, 2015.
7. **Bex T, Chung W, Baguet A, Stegen S, Stautemas J, Achten E, and Derave W**. Muscle carnosine loading by beta-alanine supplementation is more pronounced in trained vs. untrained muscles. *Journal of applied physiology* 116: 204-209, 2014.
8. **Burnham R, Martin T, Stein R, Bell G, MacLean I, and Steadward R**. Skeletal muscle fibre type transformation following spinal cord injury. *Spinal cord* 35: 86-91, 1997.
9. **Carvalho VH, Oliveira AHS, de Oliveira LF, da Silva RP, Di Mascio P, Gualano B, Artioli GG, and Medeiros MHG**. Exercise and beta-alanine supplementation on carnosine-acrolein adduct in skeletal muscle. *Redox biology* 18: 222-228, 2018.
10. **da Eira Silva V, Painelli VS, Shinjo SK, Ribeiro Pereira W, Cilli EM, Sale C, Gualano B, Otaduy MC, and Artioli GG**. Magnetic Resonance Spectroscopy as a Non-invasive Method to Quantify Muscle Carnosine in Humans: a Comprehensive Validity Assessment. *Scientific reports* 10: 4908, 2020.
11. **De Salles Painelli V, Nemezio KM, Pinto AJ, Franchi M, Andrade I, Riani LA, Saunders B, Sale C, Harris RC, Gualano B, and Artioli GG**. High-Intensity Interval Training Augments Muscle Carnosine in the Absence of Dietary Beta-alanine Intake. *Medicine and science in sports and exercise* 50: 2242-2252, 2018.
12. **Dolan E, Saunders B, Dantas WS, Murai IH, Roschel H, Artioli GG, Harris R, Bicudo J, Sale C, and Gualano B**. A Comparative Study of Hummingbirds and Chickens Provides Mechanistic Insight on the Histidine Containing Dipeptide Role in Skeletal Muscle Metabolism. *Scientific reports* 8: 14788, 2018.
13. **Dunnett M, and Harris RC**. High-performance liquid chromatographic determination of imidazole dipeptides, histidine, 1-methylhistidine and 3-methylhistidine in equine and camel muscle and individual muscle fibres. *Journal of chromatography B, Biomedical sciences and applications* 688: 47-55, 1997.
14. **Dutka TL, and Lamb GD**. Effect of carnosine on excitation-contraction coupling in mechanically-skinned rat skeletal muscle. *Journal of muscle research and cell motility* 25: 203-213, 2004.
15. **Edge J, Eynon N, McKenna MJ, Goodman CA, Harris RC, and Bishop DJ**. Altering the rest interval during high-intensity interval training does not affect muscle or performance adaptations. *Experimental physiology* 98: 481-490, 2013.

16. **Galpin AJ, Raue U, Jemiolo B, Trappe TA, Harber MP, Minchev K, and Trappe S**. Human skeletal muscle fiber type specific protein content. *Analytical biochemistry* 425: 175-182, 2012.
17. **Goncalves LS, Kratz C, Santos L, Carvalho VH, Sales LP, Nemezio K, Longobardi I, Riani LA, Lima MMO, Saito T, Fernandes AL, Rodrigues J, James RM, Sale C, Gualano B, Geloneze B, de Medeiros MHG, and Artioli GG**. Insulin does not stimulate beta-alanine transport into human skeletal muscle. *American journal of physiology Cell physiology* 318: C777-C786, 2020.
18. **Gorgey AS, Witt O, O'Brien L, Cardozo C, Chen Q, Lesnefsky EJ, and Graham ZA**. Mitochondrial health and muscle plasticity after spinal cord injury. *European journal of applied physiology* 119: 315-331, 2019.
19. **Grimby G, Broberg C, Krotkiewska I, and Krotkiewski M**. Muscle fiber composition in patients with traumatic cord lesion. *Scandinavian journal of rehabilitation medicine* 8: 37-42, 1976.
20. **Gross M, Boesch C, Bolliger CS, Norman B, Gustafsson T, Hoppeler H, and Vogt M**. Effects of beta-alanine supplementation and interval training on physiological determinants of severe exercise performance. *European journal of applied physiology* 114: 221-234, 2014.
21. **Harris RC, Dunnett M, and Greenhaff PL**. Carnosine and taurine contents in individual fibres of human vastus lateralis muscle.

Journal of Sports Sciences 16: 1998.
22. **Harris RC, Tallon MJ, Dunnett M, Boobis L, Coakley J, Kim HJ, Fallowfield JL, Hill CA, Sale C, and Wise JA**. The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. *Amino acids* 30: 279-289, 2006.
23. **Hill CA, Harris RC, Kim HJ, Harris BD, Sale C, Boobis LH, Kim CK, and Wise JA**. Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. *Amino acids* 32: 225-233, 2007.
24. **Hoetker D, Chung W, Zhang D, Zhao J, Schmidtke VK, Riggs DW, Derave W, Bhatnagar A, Bishop DJ, and Baba SP**. Exercise alters and beta-alanine combined with exercise augments histidyl dipeptide levels and scavenges lipid peroxidation products in human skeletal muscle. *Journal of applied physiology* 2018.
25. **Jones G, Smith M, and Harris R**. Imidazole dipeptide content of dietary sources commonly consumed within the British diet. *Proceedings of the Nutrition Society* 70: E363, 2011.
26. **Jung MK, Kim KY, Lee NY, Kang YS, Hwang YJ, Kim Y, Sung JJ, McKee A, Kowall N, Lee J, and Ryu H**. Expression of taurine transporter (TauT) is modulated by heat shock factor 1 (HSF1) in motor neurons of ALS. *Molecular neurobiology* 47: 699-710, 2013.
27. **Kendrick IP, Harris RC, Kim HJ, Kim CK, Dang VH, Lam TQ, Bui TT, Smith M, and Wise JA**. The effects of 10 weeks of resistance training combined with beta-alanine supplementation on whole body strength, force production, muscular endurance and body composition. *Amino acids* 34: 547-554, 2008.
28. **Kendrick IP, Kim HJ, Harris RC, Kim CK, Dang VH, Lam TQ, Bui TT, and Wise JA**. The effect of 4 weeks beta-alanine supplementation and isokinetic training on carnosine concentrations in type I and II human skeletal muscle fibres. *Eur J Appl Physiol* 106: 131-138, 2009.
29. **Mannion AF, Jakeman PM, and Willan PL**. Effects of isokinetic training of the knee extensors on high-intensity exercise performance and skeletal muscle

buffering. *European journal of applied physiology and occupational physiology* 68: 356-361, 1994.

30. **Mora L, Sentandreu MA, and Toldra F**. Hydrophilic chromatographic determination of carnosine, anserine, balenine, creatine, and creatinine. *Journal of agricultural and food chemistry* 55: 4664-4669, 2007.

31. **Parkhouse WS, McKenzie DC, Hochachka PW, and Ovalle WK**. Buffering capacity of deproteinized human vastus lateralis muscle. *Journal of applied physiology* 58: 14-17, 1985.

32. **Pires FO, Lima-Silva AE, Hammond J, Franchini E, Dal' Molin Kiss MA, and Bertuzzi R**. Aerobic profile of climbers during maximal arm test. *International journal of sports medicine* 32: 122-125, 2011.

33. **Rezende NS, Swinton P, De Oliveira LF, Da Silva RP, DA Silva VE, Nemezio K, Yamaguchi G, Artioli GG, Gualano B, Saunders B, and Dolan E**. The Muscle Carnosine Response to Beta-Alanine Supplementation: A Systematic Review with Bayesian Individual and Aggregate Data EMax Model and Meta-Analysis. *Frontiers in physiology* 11: 2020.

34. **Saunders B, Elliott-Sale K, Artioli GG, Swinton PA, Dolan E, Roschel H, Sale C, and Gualano B**. beta-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis. *British journal of sports medicine* 51: 658-669, 2017.

35. **Scelsi R, Marchetti C, Poggi P, Lotta S, and Lommi G**. Muscle fiber type morphology and distribution in paraplegic patients with traumatic cord lesion. Histochemical and ultrastructural aspects of rectus femoris muscle. *Acta neuropathologica* 57: 243-248, 1982.

36. **Tallon MJ, Harris RC, Boobis LH, Fallowfield JL, and Wise JA**. The carnosine content of vastus lateralis is elevated in resistance-trained bodybuilders. *Journal of strength and conditioning research* 19: 725-729, 2005.

37. **Yamaguchi GC, Nemezio K, Schulz ML, Natali J, Cesar JE, Riani LA, de Souza Goncalves L, Moller GB, Sale C, de Medeiros MHG, Gualano B, and Artioli GG**. Kinetics of Muscle Carnosine Decay after beta-alanine Supplementation: A 16-Week Washout Study. *Medicine and science in sports and exercise* 2020.

Author Contribution: Each of the authors had a substantial part in the planning of the study, collecting data, interpreting results, writing and revising the manuscript. Specifically, planning the study project: K.N, G.G.A. Collecting data: K.N, G.C.Y, A.P.R, M.L.Z, L.A.R. Interpreting data: K.N, I.L.B, L.S.G, C.S, M.H.G.M, B.G, G.G.A. Statistical analysis: K.N, G.G.A. Manuscript writing and revising: K.N, I.L.B, L.S.G, C.S, M.H.G.M, B.G, G.G.A.

Grants: This work was supported by: São Paulo Research Foundation - FAPESP (G.C.Y: 2015/231762; G.G.A: 2014/11948-8 and 2019/25032-9; I.L.G: 2019/12236-5; B.G: 2013/14746-4 and 2017/13552-2); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES (K.N; M.L.S and L.S.G); CEPID-Redoxoma-FAPESP (M.H.G.M: 2013/07937-8); NAP-Redoxoma (M.H.G.M: PRPUSP: Proc.2011.1.9352.1.8) and CNPq (M.H.G.M: 301404/2016-0). This work was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES- Finance Code 001).

Disclosures: Although not directly related to this study, some authors (CS and BG) have received funding from Natural Alternatives International (NAI), a company formulating and manufacturing customized nutritional supplements, including (Carnosyn SR™) β-alanine. C.S received funding to support a PhD studentship relating to the effects of carnosine on cardiac function, supplements for other studies free of charge and contribution to the payment of open access publication charges for some manuscripts on beta-alanine supplementation. B.G received a research grant and a travel grant from NAI to attend a carnosine conference. G.G.A received funding from NAI for the payment of open access publication charges for one manuscript on β-alanine supplementation. There are no other conflicts of interest to declare.


A
Whole muscle
p=0.006
Carnosine (mmol · kg-1 dry muscle)
70
60
50
40
30
20
10
0
Deltoid
V. Lateralis


B
Whole muscle
(V. Lateralis)
p=0.011
Carnosine (mmol · kg-1 dry muscle)
70
60
50
40
30
20
10
0
Active
Paralyzed


A
Whole muscle
Single fibers
II-x
II-a
I
II-x
II-a
I
B
Deltoid
MHC distribution (%)
100
90
80
70
60
50
40
30
20
10
0
Slow
Fast
C
V. Lateralis
MHC distribution (%)
120
100
80
60
40
20
0
Slow
Fast


A
Type-I Fiber
p=0.014
Carnosine (mmol · kg-1 dry muscle)
0
10
20
30
40
50
60
Deltoid
V. Lateralis
B
Type-IIa Fiber
p=0.851
Carnosine (mmol · kg-1 dry muscle)
0
10
20
30
40
50
60
70
80
Deltoid
V. Lateralis
C
Type-IIx/IIa Fiber
p=0.530
Carnosine (mmol · kg-1 dry muscle)
0
10
20
30
40
50
60
70
Deltoid
V. Lateralis
D
Deltoid
p=0.032
Carnosine (mmol · kg-1 dry muscle)
0
10
20
30
40
50
60
70
80
Type-I
Type-II
E
V. Lateralis
p=0.744
Carnosine (mmol · kg-1 dry muscle)
0
10
20
30
40
50
60
70
80
Type-I
Type-II


A
p<0.001
p<0.001
β-alanine
Placebo
Carnosine (mmol · kg-1 dry muscle)
70
60
50
40
30
20
10
0
PRE POST
PRE POST
PRE POST
PRE POST
Deltoid
V. Lateralis
Deltoid
V. Lateralis


B
p=0.653
p=0.623
V.Lateralis
Deltoid
ΔCarnosine (mmol · kg-1 dry muscle)
30
25
20
15
10
5
0
-5
β-alanine
Placebo


Deltoid
V.Lateralis
ΔCarnosine (mmol · kg-1 dry muscle)
50
40
30
20
10
0
-10
-20
Type-I Fiber
Type-II Fiber